Relmada Therapeutics Inc

Available to platforms
R StocksTrader

Relmada Therapeutics Inc (RLMD) on the NASDAQ Exchange

Company overview

Relmada Therapeutics Inc is a publicly listed company from USA with shares traded on NASDAQ under the ticker RLMD. This page provides a live view of market pricing and an interactive chart to follow short and long-term moves without manual refresh. The latest streaming quotes for RLMD are bid 4 USD and ask 4.12 USD.

Use the chart to review recent momentum, identify key price areas, and track how Relmada Therapeutics Inc is performing relative to your portfolio in 2025. If you are researching the instrument for trading or investing, add RLMD to your watchlist in R StocksTrader and compare it with other US and European shares, indices, and metals.

Key facts

  • Exchange: NASDAQ
  • Company: Relmada Therapeutics Inc
  • Ticker: RLMD
  • Country: USA
  • Bid4 USD
  • Ask4.12 USD
  • Quotes: real-time, auto-updated

Risk

Risk Warning: Past performance of RLMD does not predict future returns.

FAQ

Open a trading account at RoboForex, decide on the number of assets to buy, and then place an order for Relmada Therapeutics Inc (RLMD) in R StocksTrader. Create and verify your profile, fund the account, search for RLMD, and choose the instrument type available to you. Add RLMD to your Watchlist to track moves and manage open positions throughout 2025.

RLMD trades on NASDAQ and is issued by Relmada Therapeutics Inc. This page provides a live chart and continuously updated price data for the 2025 year so that you can follow intraday swings and longer trends. Before starting trading and placing orders, review trading hours, typical spreads, and fees in the terminal to make sure conditions for RLMD match your plan.

Quotes update automatically in real time. Current levels for RLMD are bid 4 USD and ask 4.12 USD. The spread is the difference between ask and bid and affects your effective entry and exit. Track RLMD in R StocksTrader and adjust your approach as market conditions change in 2025.